Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab With DA-REPOCH in Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT03749018Phase 2Active, not recruiting
- Start
- Jan 2019
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in B-cell non-Hodgkin lymphoma. Primary endpoint: Progression-Free Survival at 2 years. Started Jan 2019; status: active, not recruiting.
02
Drugs
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03749018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749018.